WALTHAM, Mass., Oct. 20, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that SAR3419 has started Phase II testing. This event triggers a $3 million milestone payment to ImmunoGen. SAR3419 was created by ImmunoGen and licensed to Sanofi preclinically as part of a broader collaboration between the companies.
